Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and efficacy comparison of Cholicray versus Ursophar in adult patients with hepatobiliary disorders
IRCT20210914052480N3Phase 2Completed
- Sponsor
- Rayhaneh Pharmaceutical
- Start
- Apr 2023
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of ursodeoxycholic acid in primary biliary cholangitis (PBC), metabolic dysfunction-associated steatotic liver disease (MASLD), choledocholithiasis and 1 more (2 arms), sponsored by Rayhaneh Pharmaceutical. Primary endpoints: AST, ALT and 7 more. Started Apr 2023; status: completed.
02
Drugs
ursodeoxycholic acid
03
Conditions
primary biliary cholangitis (PBC)metabolic dysfunction-associated steatotic liver disease (MASLD)choledocholithiasischolangiolitis
Beyond the preview
Go deeper on IRCT20210914052480N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210914052480N3.